October 13, 2021
|
Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
|
October 6, 2021
|
Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
|
October 4, 2021
|
Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
|
September 21, 2021
|
Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
|
September 14, 2021
|
Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
|
September 3, 2021
|
Progenity to Participate in Two Upcoming Investor Conferences
|
August 24, 2021
|
Progenity Announces Closing of $40 Million Underwritten Public Offering
|
August 19, 2021
|
Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
|
August 19, 2021
|
Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
|
August 12, 2021
|
Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
|